Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01484
|
|||||
| Drug Name |
Apafant
|
|||||
| Synonyms |
Apafant; 105219-56-5; WEB-2086; Web 2086; Apafant [USAN:INN]; Apafantum [INN-Latin]; Apafanto [INN-Spanish]; WEB 2086BS; WEB2086; UNII-J613NI05SV; WEB 2086 BS; BRN 4302553; C22H22ClN5O2S; J613NI05SV; CHEMBL280164; NCGC00092377-03; NCGC00092377-02; Apafantum; Apafanto; DSSTox_CID_28900; DSSTox_RID_83168; DSSTox_GSID_48974; 4-(3-(4-(o-Chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepin-2-yl)propionyl)morpholine; [3H]apafant; Morpholine; Apafant (ophthalmic formulation), Santen
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Conjunctivitis [ICD11: 9A60] | Discontinued in Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H22ClN5O2S
|
|||||
| Canonical SMILES |
CC1=NN=C2N1C3=C(C=C(S3)CCC(=O)N4CCOCC4)C(=NC2)C5=CC=CC=C5Cl
|
|||||
| InChI |
InChI=1S/C22H22ClN5O2S/c1-14-25-26-19-13-24-21(16-4-2-3-5-18(16)23)17-12-15(31-22(17)28(14)19)6-7-20(29)27-8-10-30-11-9-27/h2-5,12H,6-11,13H2,1H3
|
|||||
| InChIKey |
JGPJQFOROWSRRS-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 105219-56-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 456 | Topological Polar Surface Area | 101 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
1.1
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:92490
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000113) | |||||
| 2 | Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharm Sci. 2002 Aug;16(3):119-28. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.